LABIANA HEALTH S.A.EO-10 Net Assets
LABIANA HEALTH S.A.EO-10 net assets. Based on the latest financial reports, LABIANA HEALTH S.A.EO-10 (8RK) has net assets worth €4.76 Million EUR (≈ $5.56 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€57.54 Million ≈ $67.27 Million USD) and total liabilities (€52.79 Million ≈ $61.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore LABIANA HEALTH S.A.EO-10 (8RK) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.76 Million |
| % of Total Assets | 8.27% |
| Annual Growth Rate | -19.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 54.36 |
Net Assets of LABIANA HEALTH S.A.EO-10 (2021–2025)
Net assets of LABIANA HEALTH S.A.EO-10 from 2021 to 2025. This chart illustrates how LABIANA HEALTH S.A.EO-10's net assets have evolved over time, based on quarterly financial data. See 8RK equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for LABIANA HEALTH S.A.EO-10 (2021–2025)
The table below shows the annual net assets of LABIANA HEALTH S.A.EO-10 from 2021 to 2025. For live market cap and overall valuation, see 8RK stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.76 Million ≈ $5.56 Million |
+85.24% |
| 2024-12-31 | €2.57 Million ≈ $3.00 Million |
-24.54% |
| 2023-12-31 | €3.40 Million ≈ $3.98 Million |
-50.73% |
| 2022-12-31 | €6.91 Million ≈ $8.07 Million |
-40.06% |
| 2021-12-31 | €11.52 Million ≈ $13.47 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LABIANA HEALTH S.A.EO-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 434441670.0% over the analyzed period, indicating profitable operations and earnings retention.
LABIANA HEALTH S.A.EO-10 Net Assets Breakdown (December 2025)
LABIANA HEALTH S.A.EO-10 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €2.57 Million | 50.54% |
| Other Components | €2.51 Million | 49.46% |
| Total Equity | €5.08 Million | 100.00% |
LABIANA HEALTH S.A.EO-10 Competitors by Market Cap
The table below lists competitors of LABIANA HEALTH S.A.EO-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bluebird bio Inc
NASDAQ:BLUE
|
$48.67 Million |
|
GenoFocus Inc
KQ:187420
|
$48.67 Million |
|
Quartiers Properties AB
ST:QUART
|
$48.68 Million |
|
Sietel Ltd
AU:SSL
|
$48.73 Million |
|
Upsales Technology AB
ST:UPSALE
|
$48.56 Million |
|
Chin Yang Chem
KO:051630
|
$48.56 Million |
|
Indonesia Energy
NYSE MKT:INDO
|
$48.56 Million |
|
Digihost Technology Inc
V:DGHI
|
$48.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LABIANA HEALTH S.A.EO-10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,868,879 to 5,083,280, a change of 2,214,401 (77.2%).
- Net income of 2,569,177 contributed positively to equity growth.
- New share issuances of 205,228 increased equity.
- Other factors decreased equity by 560,004.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.57 Million | +50.54% |
| Share Issuances | €205.23K | +4.04% |
| Other Changes | €-560.00K | -11.02% |
| Total Change | €- | 77.19% |
Book Value vs Market Value Analysis
This analysis compares LABIANA HEALTH S.A.EO-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.91x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.05x to 6.91x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.60 | €4.90 | x |
| 2022-12-31 | €0.97 | €4.90 | x |
| 2023-12-31 | €0.50 | €4.90 | x |
| 2024-12-31 | €0.40 | €4.90 | x |
| 2025-12-31 | €0.71 | €4.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LABIANA HEALTH S.A.EO-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 50.54%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.42%
- • Asset Turnover: 1.31x
- • Equity Multiplier: 11.32x
- Recent ROE (50.54%) is above the historical average (-41.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -15.32% | -3.12% | 0.83x | 5.90x | €-2.93 Million |
| 2022 | -127.12% | -15.46% | 0.95x | 8.64x | €-9.65 Million |
| 2023 | -123.47% | -7.57% | 0.99x | 16.51x | €-4.78 Million |
| 2024 | 8.83% | 0.38% | 1.27x | 18.13x | €-33.44K |
| 2025 | 50.54% | 3.42% | 1.31x | 11.32x | €2.06 Million |
Industry Comparison
This section compares LABIANA HEALTH S.A.EO-10's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,676,957,497
- Average return on equity (ROE) among peers: -45.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LABIANA HEALTH S.A.EO-10 (8RK) | €4.76 Million | -15.32% | 11.10x | $48.63 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $61.84 Billion | 5.45% | 0.94x | $1.20 Billion |
| PEPTONIC MEDICAL (28L) | $75.32 Million | -56.54% | 0.42x | $5.52 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| HANSOH PHARMAC. HD-00001 (3KY) | $28.68 Billion | 15.24% | 0.10x | $22.06 Billion |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $216.42 Million | -22.23% | 0.32x | $57.92 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.51 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $11.22 Million | -54.38% | 0.30x | $6.62 Million |
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage f… Read more